Rising global burden of cancer attributable to high BMI from 2010 to 2019
Document Type
Article
Publication Date
3-1-2024
Abstract
Background: High body mass index (BMI) is a major risk factor for cancer development, but its impact on the global burden of cancer remains unclear. Methods: We estimated global and regional temporal trends in the burden of cancer attributable to high BMI, and the contributions of various cancer types using the framework of the Global Burden of Disease Study. Results: From 2010 to 2019, there was a 35 % increase in deaths and a 34 % increase in disability-adjusted life-years from cancers attributable to high BMI. The age-standardized death rates for cancer attributable to high BMI increased over the study period (annual percentage change APC] +0.48 %, 95 % CI 0.22 to 0.74 %). The greatest number of deaths from cancer attributable to high BMI occurred in Europe, but the fastest-growing age-standardized death rates and disability-adjusted life-years occurred in Southeast Asia. Liver cancer was the fastest-growing cause of cancer mortality (APC: 1.37 %, 95 % CI 1.25 to 1.49 %) attributable to high BMI. Conclusion: The global burden of cancer-related deaths attributable to high BMI has increased substantially from 2010 to 2019. The greatest increase in age-standardized death rates occurred in Southeast Asia, and liver cancer is the fastest-growing cause of cancer mortality attributable to high BMI. Urgent and sustained measures are required at a global and regional level to reverse these trends and slow the growing burden of cancer attributed to high BMI.
Keywords
Cancer, Epidemiology, Etiology, Obesity
Divisions
fac_med,ummc
Funders
United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) (U01DK061734); (R01DK106419); (P30DK120515); (R01DK121378); (R01DK124318),Bristol-Myer Squibb (P01HL147835),Eli Lilly,Galmed,Metacrine, Inc.,NGM Bio-pharmaceuticals,Arrowhead Pharmaceuticals,AstraZeneca,Galectin Therapeutics,Galmed Pharmaceu-ticals,NGM Biopharmaceuticals,Novo Nordisk Novo Nordisk Foundation,National Medical Research Council, Singapore (MOH-OFLCG18May-0003),Agency for Science Technology & Research (A*STAR),Ministry of Health-Singapore National Medical Research Council, Singapore UK Research & Innovation (UKRI) Medical Research Council UK (MRC) (IAF-ICP I2101E0012),Massachusetts Life Sciences Center (MOH-000595-01),Coherus Inc.,Merck & Company,Boehringer Ingelheim,Elsevier
Publication Title
Metabolism-Clinical and Experimental
Volume
152
Publisher
Elsevier
Publisher Location
1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA